Heart failure and chemotherapeutic agents

Future Cardiology

Volumn 11, Issue 4, 2015, Pages 453-470

  Piper, Susan ^a,b   McDonagh, Theresa ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anthracyclines; Cardiotoxicity; Chemotherapy; Heart failure; Left ventricular systolic dysfunction; Trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; IFOSFAMIDE; LAPATINIB; MINERALOCORTICOID ANTAGONIST; PACLITAXEL; RAZOXANE; SUNITINIB; TRASTUZUMAB; TROPONIN; TUMOR MARKER;

CANCER CHEMOTHERAPY; CARDIAC IMAGING; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; HEART FAILURE; HEART LEFT VENTRICLE; HEREDITY; HUMAN; IMAGE ANALYSIS; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT DURATION; CHEMICALLY INDUCED; NEOPLASMS;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOTOXICITY; HEART FAILURE; HUMANS; NEOPLASMS; TRASTUZUMAB;

EID: 84939443638     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.15.28     Document Type: Review

References (129)

1. Yusuf SW, Cipolla C, Durand JB, Lenihan DJ. Cancer and cardiovascular disease. Cardiol. Res. Pract. 2011, 943748 (2011).
2. Raj S, Franco VI, Lipshultz SE. Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment. Curr. Treat. Options Cardiovasc. Med. 16(6), 315 (2014).
3. Maddams J, Utley M, Moller H. Projections of cancer prevalence in the United Kingdom, 2010-2040. Br. J. Cancer 107(7), 1195-1202 (2012).
4. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 53(24), 2231-2247 (2009).
5. Oeffinger KC, Mertens AC, Sklar CA et al. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355(15), 1572-1582 (2006).
6. Moller TR, Garwicz S, Barlow L et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J. Clin. Oncol. 19(13), 3173-3181 (2001).
7. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev. Anticancer Ther. 6(9), 1249-1269 (2006).
8. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opini. Pharmacother. 8(8), 1039-1058 (2007).
9. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 22(4), 263-302 (2000).
10. Cardinale D, Colombo A, Cipolla CM. Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy. Curr. Treat. Options Cardiovasc. Med. 10(6), 486-495 (2008).
11. Institute NC. Common terminology criteria for adverse events (CTCAE) v4. 0. (2015).
12. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 20(5), 1215-1221 (2002).
13. Martin M, Esteva FJ, Alba E et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 14(1), 1-11 (2009).
14. Eschenhagen T, Force T, Ewer MS et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 13(1), 1-10 (2011).
15. Curigliano G, Cardinale D, Suter T et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann. Oncol. 23(Suppl. 7), vii155-vii166 (2012).
16. Schwartz RG, Mckenzie WB, Alexander J et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am. J. Med. 82(6), 1109-1118 (1987).
17. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
18. O'brien ME, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15(3), 440-449 (2004).
19. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. 23(31), 7811-7819 (2005).
20. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
21. Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J. Natl Cancer Inst. 100(15), 1058-1067 (2008).
22. Sawaya H, Plana JC, Scherrer-Crosbie M. Newest echocardiographic techniques for the detection of cardiotoxicity and heart failure during chemotherapy. Heart Fail. Clin. 7(3), 313-321 (2011).
23. Lenaz L, Page JA. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat. Rev. 3(3), 111-120 (1976).
24. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am. J. Med. 62(2), 200-208 (1977).
25. Gilladoga AC, Manuel C, Tan CT, Wollner N, Sternberg SS, Murphy ML. The cardiotoxicity of adriamycin and daunomycin in children. Cancer 37(2 Suppl.), 1070-1078 (1976).
26. Praga C, Beretta G, Vigo PL et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat. Rep. 63(5), 827-834 (1979).
27. Bjorkhem G, Garwicz S. Echocardiographic assessment of left ventricular function during the injection of adriamycin. Acta Paediatr. Scand. 66(5), 595-600 (1977).
28. Bowles EJ, Wellman R, Feigelson HS et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J. Natl Cancer Inst. 104(17), 1293-1305 (2012).
29. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57(7), 727-741 (1999).
30. Horenstein MS, Vander Heide RS, L'ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol. Genet. Metabol. 71(1-2), 436-444 (2000).
31. Cruet-Hennequart S, Prendergast AM, Shaw G, Barry FP, Carty MP. Doxorubicin induces the DNA damage response in cultured human mesenchymal stem cells. Int. J. Hematol. 96(5), 649-656 (2012).
32. Hershko C, Link G, Tzahor M, Pinson A. The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk. Lymphoma 11(3-4), 207-214 (1993).
33. Link G, Tirosh R, Pinson A, Hershko C. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of ironanthracycline interaction. J. Lab. Clin. Med. 127(3), 272-278 (1996).
34. Hershko C, Pinson A, Link G. Prevention of anthracycline cardiotoxicity by iron chelation. Acta Haematol. 95(1), 87-92 (1996).
35. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. 131(5), 561-578 (2005).
36. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol. Cell. Biochem. 234-235(1-2), 119-124 (2002).
37. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11), 2869-2879 (2003).
38. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91(5), 710-717 (1979).
39. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 324(12), 808-815 (1991).
40. Casper ES, Gaynor JJ, Hajdu SI et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 68(6), 1221-1229 (1991).
41. Hortobagyi GN, Frye D, Buzdar AU et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63(1), 37-45 (1989).
42. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer 65(4), 870-873 (1990).
43. Lipshultz SE, Giantris AL, Lipsitz SR et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J. Clin. Oncol. 20(6), 1677-1682 (2002).
44. Lipshultz SE, Miller TL, Lipsitz SR et al. Continuous versus bolus infusion of doxorubicin in children with all. long-term cardiac outcomes. Pediatrics 130(6), 1003-1011 (2012).
45. Van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst. Rev. (5), CD005006 (2010).
46. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline-and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr. Blood Cancer 44(7), 600-606 (2005).
47. Landy DC, Miller TL, Lipsitz SR et al. Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study. Pediatr. Cardiol. 34(4), 826-834 (2013).
48. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J. Clin. Oncol. 15(4), 1544-1552 (1997).
49. Lipshultz SE, Lipsitz SR, Kutok JL et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer 119(19), 3555-3562 (2013).
50. Gabizon A, Goren D, Cohen R, Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. J. Control. Release 53(1-3), 275-279 (1998).
51. Berry G, Billingham M, Alderman E et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann. Oncol. 9(7), 711-716 (1998).
52. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 8(Suppl. 2), 17-24 (2003).
53. Alberts DS, Muggia FM, Carmichael J et al. Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials. Semin. Oncol. 31(6 Suppl. 13), 53-90 (2004).
54. Batist G, Harris L, Azarnia N, Lee LW, Daza-Ramirez P. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anti-cancer Drugs 17(5), 587-595 (2006).
55. Rivankar S. An overview of doxorubicin formulations in cancer therapy. J. Caner Res. Ther. 10(4), 853-858 (2014).
56. Lahtinen R, Kuikka J, Nousiainen T, Uusitupa M, Lansimies E. Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study. Eur. J. Haematol. 46(5), 301-305 (1991).
57. Robert J, Rigal-Huguet F, Hurteloup P. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Haematol. Oncol. 10(2), 111-116 (1992).
58. Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr. Cancer Ther. 4(2), 110-130 (2005).
59. Emanuelov AK, Shainberg A, Chepurko Y et al. Adenosine A3 receptor-mediated cardioprotection against doxorubicin-induced mitochondrial damage. Biochem. Pharmacol. 79(2), 180-187 (2010).
60. Fu P, Arcasoy MO. Erythropoietin protects cardiac myocytes against anthracyclineinduced apoptosis. Biochem. Biophys. Res. Commun. 354(2), 372-378 (2007).
61. Gebbia N, Flandina C, Leto G et al. The role of histamine in doxorubicin and teniposideinduced cardiotoxicity in dog and mouse. Tumori 73(3), 279-287 (1987).
62. Van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. (6), CD003917 (2011).
63. Williams CJ. Doxorubicin cardiotoxicity: role of digoxin in prevention. Br. Med. J. 1(6106), 176 (1978).
64. Cvetkovic RS, Scott LJ. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 65(7), 1005-1024 (2005).
65. Testore F, Milanese S, Ceste M et al. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience. Am. J. Cardiovasc. Drugs 8(4), 257-263 (2008).
66. Venturini M, Michelotti A, Del Mastro L et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J. Clin. Oncol. 14(12), 3112-3120 (1996).
67. Research CFDEA. Drug Safety and Availability-FDA Statement on Dexrazoxane. (2011). www. fda. gov/Drugs/DrugSafety/ucm263729. htm
68. Tebbi CK, London WB, Friedman D et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J. Clin. Oncol. 25(5), 493-500 (2007).
69. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med. 316(23), 1429-1435 (1987).
70. Packer M, Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106(17), 2194-2199 (2002).
71. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341(10), 709-717 (1999).
72. Zannad F, Mcmurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364(1), 11-21 (2011).
73. Mcmurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14(8), 803-869 (2012).
74. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128(16), e240-e327 (2013).
75. Krum H. Guidelines for management of patients with chronic heart failure in Australia. Med. J. Aust. 174(9), 459-466 (2001).
76. Mpe MT, Klug EQ, Silwa KS, Hitzeroth J, Smith DA. Heart Failure Society of South Africa (HeFSSA) perspective on the European Society of Cardiology (ESC) 2012 chronic heart failure guideline. S. Afr. Med. J. 103(9 Suppl. 2), 660-667 (2013).
77. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapyinduced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23), 2474-2481 (2006).
78. Spallarossa P, Garibaldi S, Altieri P et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J. Mol. Cell. Cardiol. 37(4), 837-846 (2004).
79. Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracyclineinduced cardiomyopathy. J. Am. Coll. Cardiol. 48(11), 2258-2262 (2006).
80. Bosch X, Rovira M, Sitges M et al. Enalapril and carvedilol for preventing chemotherapyinduced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of malignant hEmopathies). J. Am. Coll. Cardiol. 61(23), 2355-2362 (2013).
81. Akpek M, Ozdogru I, Sahin O et al. Protective effects of spironolactone against anthracyclineinduced cardiomyopathy. Eur. J. Heart Fail. 17(1), 81-89 (2015).
82. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin. Oncol. 27(5 Suppl. 9), 13-19 (2000).
83. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12(Suppl. 1), S35-S41 (2001).
84. Research CFDEA. Therapeutic Biologic Applications (BLA)-Trastuzumab Product Approval Information-Licensing Action 9/25/98 (1998). www. fda. gov
85. Fuller SJ, Sivarajah K, Sugden PH. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. J. Mol. Cell. Cardiol. 44(5), 831-854 (2008).
86. Lenneman CG. Neuregulin-1 signaling in the pathogenesis of chemotherapy-induced heart failure. Curr. Heart Fail. Rep. 11(2), 134-138 (2014).
87. Crone SA, Zhao YY, Fan L et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8(5), 459-465 (2002).
88. Ewer MS, Ewer SM. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J. Clin. Oncol. 28(25), 3901-3904 (2010).
89. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
90. Smith LA, Cornelius VR, Plummer CJ et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10, 337 (2010).
91. De Azambuja E, Procter MJ, Van Veldhuisen DJ et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01). J. Clin. Oncol. 32(20), 2159-2165 (2014).
92. Gunaldi M, Duman BB, Afsar CU et al. Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: an observational single-centre study. J. Oncol. Pharm. Pract. doi:10. 1177/1078155214567162 (2015) (Epub ahead of print).
93. Naumann D, Rusius V, Margiotta C et al. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer. Anticancer Res. 33(4), 1717-1720 (2013).
94. Serrano C, Cortes J, De Mattos-Arruda L et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann. Oncol. 23(4), 897-902 (2012).
95. Pivot X, Romieu G, Debled M et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised Phase 3 trial. Lancet Oncol. 14(8), 741-748 (2013).
96. ClinicalTrials. gov: NCT00593697. https://clinicaltrials. gov
97. Guarneri V, Frassoldati A, Bruzzi P et al. Multicentric, randomized Phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2-positive breast cancer (Short-HER Trial; NCT00629278). Clin. Breast Cancer 8(5), 453-456 (2008).
98. ClinicalTrials. gov: NCT00712140. https://clinicaltrials. gov
99. Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ. Heart Fail. 6(3), 420-426 (2013).
100. Pituskin E, Haykowsky M, Mackey JR et al. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): a randomized, placebocontrolled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 11, 318 (2011).
101. Marty M, Cognetti F, Maraninchi D et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J. Clin. Oncol. 23(19), 4265-4274 (2005).
102. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352(24), 2487-2498 (2005).
103. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc. 83(6), 679-686 (2008).
104. Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26(32), 5204-5212 (2008).
105. Lipshultz SE, Adams MJ, Colan SD et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 128(17), 1927-1995 (2013).
106. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J. Clin. Oncol. 26(8), 1201-1203 (2008).
107. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J. Am. Coll. Cardiol. 63(25 Pt A), 2751-2768 (2014).
108. Plana JC, Galderisi M, Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging 15(10), 1063-1093 (2014).
109. Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J. Cardiovasc. Magn. Reson. 10, 5 (2008).
110. Fallah-Rad N, Walker JR, Wassef A et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J. Am. Coll. Cardiol. 57(22), 2263-2270 (2011).
111. Tian S, Hirshfield KM, Jabbour SK et al. Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients. Front. Oncol. 4, 277 (2014).
112. Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109(22), 2749-2754 (2004).
113. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am. J. Clin. Pathol. 130(5), 688-695 (2008).
114. Herman EH, Zhang J, Lipshultz SE et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J. Clin. Oncol. 17(7), 2237-2243 (1999).
115. Morandi P, Ruffini PA, Benvenuto GM, La Vecchia L, Mezzena G, Raimondi R. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide. Bone Marrow Transplant. 28(3), 277-282 (2001).
116. Specchia G, Buquicchio C, Pansini N et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J. Lab. Clin. Med. 145(4), 212-220 (2005).
117. Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J. Clin. Oncol. 28(25), 3910-3916 (2010).
118. Morris PG, Chen C, Steingart R et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin. Cancer Res. 17(10), 3490-3499 (2011).
119. Mccullough PA, Nowak RM, Mccord J et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106(4), 416-422 (2002).
120. Zaphiriou A, Robb S, Murray-Thomas T et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur. J. Heart Fail. 7(4), 537-541 (2005).
121. Aggarwal S, Pettersen MD, Bhambhani K, Gurczynski J, Thomas R, L'ecuyer T. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr. Blood Cancer 49(6), 812-816 (2007).
122. Lipshultz SE, Miller TL, Scully RE et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J. Clin. Oncol. 30(10), 1042-1049 (2012).
123. Sandri MT, Salvatici M, Cardinale D et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin. Chem. 51(8), 1405-1410 (2005).
124. Suzuki T, Hayashi D, Yamazaki T et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am. Heart J. 136(2), 362-363 (1998).
125. Sawaya H, Sebag IA, Plana JC et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ. Cardiovasc. Imaging 5(5), 596-603 (2012).
126. Daugaard G, Lassen U, Bie P et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur. J. Heart Fail. 7(1), 87-93 (2005).
127. Lipshultz SE, Landy DC, Lopez-Mitnik G et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J. Clin. Oncol. 30(10), 1050-1057 (2012).
128. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol. 55(3), 213-220 (2010).
129. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23(31), 7820-7826 (2005).